Pharmaceutical producers are allocating unprecedented capital toward fill-finish manufacturing capacity to satisfy structural demand for GLP-1 receptor agonists. Supply shortfalls have reshaped domestic pharmacy availability globally.
Contract Manufacturing Integration
Leading drug makers are relying heavily on specialized third-party contract development and manufacturing organizations (CDMOs). Industry analysts project capacity constraints will normalize by mid-2026 as greenfield facilities come online.